Literature DB >> 24781600

Preoperative plasma D-dimer level is an independent prognostic factor in patients with completely resected non-small cell lung cancer.

Koichi Fukumoto1, Tetsuo Taniguchi, Noriyasu Usami, Koji Kawaguchi, Takayuki Fukui, Futoshi Ishiguro, Shota Nakamura, Kohei Yokoi.   

Abstract

PURPOSE: The plasma D-dimer (D-dimer) level, a marker of hypercoagulation, has been reported to be associated with survival in several types of cancers. This retrospective study was conducted to evaluate the prognostic significance of the preoperative D-dimer level in patients with completely resected non-small cell lung cancer (NSCLC).
METHODS: A total of 237 completely resected NSCLC patients were included in this study. In addition to age, sex, the smoking status, etc., the association between the preoperative D-dimer level and survival was explored.
RESULTS: The patients were divided into three groups according to the D-dimer level: group A (≤ 0.50 μg/ml, n = 76), group B (0.51-0.86 μg/ml, n = 79) and group C (>0.86 μg/ml, n = 82). The 5-year overall survival rate was 89.6 % (95 % confidence interval (CI) 77.7-95.3) for group A, 75.1 % (95 % CI 62.3-83.6) for group B and 60.1 % (95 % CI 46.8-71.1) for group C (P trend <0.001). A multivariate survival analysis showed that the D-dimer level (group B vs. group A HR 4.25, group C vs. group A HR 4.11) was an independent significant prognostic factor, in addition to age, sex, the pathological stage and the serum carcinoembryonic antigen level.
CONCLUSIONS: The preoperative D-dimer level is an independent prognostic factor in patients with completely resected NSCLC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24781600     DOI: 10.1007/s00595-014-0894-4

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  17 in total

1.  Prognostic significance of plasma D-dimer levels in patients with lung cancer.

Authors:  O Taguchi; E C Gabazza; H Yasui; T Kobayashi; M Yoshida; H Kobayashi
Journal:  Thorax       Date:  1997-06       Impact factor: 9.139

2.  Positron emission tomography/computed tomography and lymphovascular invasion predict recurrence in stage I lung cancers.

Authors:  Satoshi Shiono; Masami Abiko; Toru Sato
Journal:  J Thorac Oncol       Date:  2011-01       Impact factor: 15.609

Review 3.  Trousseau's syndrome: multiple definitions and multiple mechanisms.

Authors:  Ajit Varki
Journal:  Blood       Date:  2007-05-11       Impact factor: 22.113

4.  Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade.

Authors:  Noriyoshi Sawabata; Etsuo Miyaoka; Hisao Asamura; Yoichi Nakanishi; Kenji Eguchi; Masaki Mori; Hiroaki Nomori; Yoshitaka Fujii; Meinoshin Okumura; Kohei Yokoi
Journal:  J Thorac Oncol       Date:  2011-07       Impact factor: 15.609

5.  High D-dimer levels are associated with poor prognosis in cancer patients.

Authors:  Cihan Ay; Daniela Dunkler; Robert Pirker; Johannes Thaler; Peter Quehenberger; Oswald Wagner; Christoph Zielinski; Ingrid Pabinger
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

6.  Impact of positive pleural lavage cytology on survival in patients having lung resection for non-small-cell lung cancer: An international individual patient data meta-analysis.

Authors:  Eric Lim; Rachel Clough; Peter Goldstraw; Lyn Edmonds; Keiju Aokage; Junji Yoshida; Kanji Nagai; Yasushi Shintani; Mitsunori Ohta; Meinoshin Okumura; Teruo Iwasaki; Tsutomu Yasumitsu; Morihito Okada; Takeshi Mimura; Noriaki Tsubota; Tatsuo Nakagawa; Norihito Okumura; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Masahiko Higashiyama; Ken Kodama; Marc Riquet; Giovanni Vicidomini; Mario Santini; Christophoros Kotoulas; Jeng-Yuan Hsu; Chih-Yi Chen
Journal:  J Thorac Cardiovasc Surg       Date:  2009-11-25       Impact factor: 5.209

7.  Pathologic stage I non-small cell lung cancer with high levels of preoperative serum carcinoembryonic antigen: clinicopathologic characteristics and prognosis.

Authors:  Haruhisa Matsuguma; Rie Nakahara; Seiji Igarashi; Yoshinori Ishikawa; Haruko Suzuki; Naoto Miyazawa; Satoshi Honjo; Kohei Yokoi
Journal:  J Thorac Cardiovasc Surg       Date:  2008-01       Impact factor: 5.209

8.  Preoperative plasma D-dimer levels predict survival in patients with operable non-small cell lung cancer independently of venous thromboembolism.

Authors:  P P Zhang; J W Sun; X Y Wang; X M Liu; K Li
Journal:  Eur J Surg Oncol       Date:  2013-06-28       Impact factor: 4.424

9.  High plasma D-dimer level is associated with decreased survival in patients with lung cancer.

Authors:  G Altiay; A Ciftci; M Demir; Z Kocak; N Sut; E Tabakoglu; O N Hatipoglu; T Caglar
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-05-21       Impact factor: 4.126

10.  D-dimer levels as a prognostic factor for determining oncological outcomes in musculoskeletal sarcoma.

Authors:  Takeshi Morii; Kazuo Mochizuki; Takashi Tajima; Shoichi Ichimura; Kazuhiko Satomi
Journal:  BMC Musculoskelet Disord       Date:  2011-11-01       Impact factor: 2.362

View more
  21 in total

1.  Diffusion-weighted imaging can correctly identify false-positive lymph nodes on positron emission tomography in non-small cell lung cancer.

Authors:  Hiroaki Nomori; Yue Cong; Hiroshi Sugimura; Yoshiaki Kato
Journal:  Surg Today       Date:  2015-12-10       Impact factor: 2.549

2.  Risk factors associated with recurrence of surgically resected node-positive non-small cell lung cancer.

Authors:  Yoichi Ohtaki; Kimihiro Shimizu; Kyoichi Kaira; Toshiteru Nagashima; Kai Obayashi; Seshiru Nakazawa; Seiichi Kakegawa; Hitoshi Igai; Mitsuhiro Kamiyoshihara; Masahiko Nishiyama; Izumi Takeyoshi
Journal:  Surg Today       Date:  2016-01-19       Impact factor: 2.549

3.  A retrospective analysis of plasma D-dimer dynamic variation in terminal stage cancer patients: implications for disease progression.

Authors:  Xi Zhang; Zhu-Qing Liu; Wei Zhang; Qing Xu
Journal:  Int J Clin Exp Med       Date:  2014-08-15

4.  Plasma D-dimer value as a predictor of malignant lymph node involvement in operable non-small cell lung cancer.

Authors:  Feng Chen; Min-Jie Wang; Jia Li; Cui-E Yan; Xiao-Hong Han; Zong-Yong Wu; Jun Qi
Journal:  Tumour Biol       Date:  2015-06-19

5.  Perioperative circulating tumor cells in surgical patients with non-small cell lung cancer: does surgical manipulation dislodge cancer cells thus allowing them to pass into the peripheral blood?

Authors:  Noriyoshi Sawabata; Soichiro Funaki; Takeru Hyakutake; Yasushi Shintani; Ayako Fujiwara; Meinoshin Okumura
Journal:  Surg Today       Date:  2016-03-07       Impact factor: 2.549

6.  Postoperative D-dimer elevation affects tumor recurrence and the long-term survival in gastric cancer patients who undergo gastrectomy.

Authors:  Kentaro Hara; Toru Aoyama; Tsutomu Hayashi; Masato Nakazono; Shinsuke Nagasawa; Yota Shimoda; Yuta Kumazu; Masakatsu Numata; Takanobu Yamada; Hiroshi Tamagawa; Manabu Shiozawa; Soichiro Morinaga; Norio Yukawa; Yasushi Rino; Munetaka Masuda; Takashi Ogata; Takashi Oshima
Journal:  Int J Clin Oncol       Date:  2019-12-21       Impact factor: 3.402

7.  Preoperative D-dimer level is an independent prognostic factor for non-small cell lung cancer after surgical resection: a systematic review and meta-analysis.

Authors:  Han-Yu Deng; Xi Zheng; Rui Jiang; Rui-Lan Wang; Jie Zhou; Xiao-Ming Qiu
Journal:  Ann Transl Med       Date:  2019-08

8.  Elevated pretreatment plasma D-dimer levels and platelet counts predict poor prognosis in pancreatic adenocarcinoma.

Authors:  Peng Liu; Yuan Zhu; Luying Liu
Journal:  Onco Targets Ther       Date:  2015-06-04       Impact factor: 4.147

9.  Elevated preoperative plasma D-dimer dose not adversely affect survival of gastric cancer after gastrectomy with curative intent: A propensity score analysis.

Authors:  Yuexiang Liang; Donglei He; Liangliang Wu; Xuewei Ding; Xiaona Wang; Baogui Wang; Rupeng Zhang; Han Liang
Journal:  Chin J Cancer Res       Date:  2018-04       Impact factor: 5.087

10.  On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy.

Authors:  Pablo Nenclares; Lucinda Gunn; Heba Soliman; Mateo Bover; Amy Trinh; Isla Leslie; Kee Howe Wong; Alan Melcher; Kate Newbold; Chris M Nutting; Derfel Ap Dafydd; Shreerang A Bhide; Kevin Harrington
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.